HUNTER HEATH III, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Fogelman and colleagues (1) show increased total-body retention of technetium-99m diphosphonate in a small group of patients with primary hyperparathyroidism and equate this finding with evidence of "skeletal disease." They propose this as a ". . . simple, sensitive . . . test in the diagnosis and evaluation of . . . suspected primary hyperparathyroidism." In my opinion, their logic is flawed and their conclusions premature, if not inappropriate. Several specific criticisms follow.
1. The authors state that their method "can differentiate patient groups with renal osteodystrophy, osteomalacia, Paget's disease, and primary hyperparathyroidism from a control population"
HEATH H. Technetium-99m Diphosphonate Retention in Hyperparathyroidism. Ann Intern Med. ;92:873–874. doi: 10.7326/0003-4819-92-6-873
Download citation file:
Published: Ann Intern Med. 1980;92(6):873-874.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use